Related Experiment Videos
Integrated system for the screening of the specificity of protein kinase inhibitors
J M Barret1, A P Ernould, G Ferry
1Département de Cancérologie Expérimentale, Institut de Recherches Servier, Suresnes, France.
Abstract:
Tyrosine protein kinases (TPKs) play a major role in the transformation of cells. They are currently used as molecular targets for new generations of anticancer compounds. Numerous TPKs have been described from various tissues using either classical molecular biochemical techniques or cloning strategies. As a natural extension of these discoveries, a large number of "specific" inhibitors have been described in the literature. The major problem with these inhibitors is that there is no simple way to compare their specificity and/or selectivity from one report to another. We have set up a simple, straightforward technique to compare the inhibitory potency of 14 classical inhibitors towards six well-described and at least partially purified protein kinases. This technique is based on a new assay, easy to carry out and non-restrictive in terms of the type of protein substrate used. It permits direct comparisons between the results obtained from various sources. Data obtained showed that, when assessed in this integrated system, specificity and selectivity of many "classical" inhibitors are often weak, thus demonstrating that a universal technique such as ours is essential for the molecular screening of new protein kinase inhibitors. Compounds showing specificity for this panel of protein kinases will be more easily targeted to some defined types of oncogene and of transformed cells.
Insights
A new assay allows direct comparison of tyrosine protein kinase (TPK) inhibitors. This method reveals that many classical inhibitors have weak specificity, highlighting the need for universal screening techniques for anticancer drug development.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Tyrosine protein kinases (TPKs) are crucial in cell transformation and are key targets for anticancer therapies.
- Numerous TPKs have been identified, leading to the development of many specific inhibitors.
- A significant challenge is the lack of a standardized method to compare the specificity and selectivity of these inhibitors across studies.
Purpose of the Study:
- To develop and validate a simple, universal assay for comparing the inhibitory potency of TPK inhibitors.
- To assess the specificity and selectivity of 14 classical inhibitors against six well-characterized protein kinases.
Main Methods:
- A novel, straightforward assay was established for evaluating inhibitor potency.
- The assay is easy to perform and accommodates various protein substrates.
- It enables direct comparison of inhibitor data from different sources.
Main Results:
- The study assessed 14 classical inhibitors against six protein kinases using the new assay.
- Results indicated that many classical inhibitors exhibit weak specificity and selectivity when evaluated in this integrated system.
- The findings underscore the limitations of current inhibitor characterization methods.
Conclusions:
- A universal assay is essential for the accurate molecular screening of novel protein kinase inhibitors.
- The developed technique facilitates reliable comparison of inhibitor potency, specificity, and selectivity.
- Identifying compounds with specific kinase inhibition profiles can aid in targeting oncogenes and transformed cells effectively.